Published Year: 2021
CRISPR Gene Editing Market - A Global and Regional Analysis: Focus on Product, Application, End User
The global CRISPR gene editing market was valued at $1,088.6 million in 2020 and is expected...
Market Research Report
A quick peek into the report
Gene Editing Technologies Industry and Technology Overview
The global gene editing technologies market was valued at $1.81 billion in 2022 and is anticipated to reach $16.37 billion by 2032, witnessing a CAGR of 27.50% during the forecast period 2023-2032. The growth in the global gene editing technologies market is expected to be driven by an increase in the need for personalized medicine. In addition, the introduction of new technologies fuelled the growth of gene editing technologies.
Market Lifecycle Stage
The global gene editing technologies market is in progressing phase. The creation, production, and distribution of tools and services for gene editing are under the purview of the gene editing technology market. Utilizing ways to change DNA sequences, gene editing technologies can be used to treat genetic illnesses, create disease-resistant crops, and generate study models for animals. The market for gene editing technology is made up of numerous businesses that sell CRISPR-Cas9, TALENs, and zinc finger nucleases, among other types of gene editing tools. Researchers, pharmaceutical corporations, and biotech companies employ these techniques to create novel treatments, vaccines, and diagnostic devices.
Moreover, manufacturers began to produce application-specific gene editing technologies in recent years.
Impact
Clustered regularly interspaced short palindromic repeats Cas9 (CRISPR-Cas9) and other gene editing technologies have the potential to revolutionize the healthcare sector and have a big impact on the world economy. Treatments for genetic problems and diseases such as cancer, HIV, and cystic fibrosis may become more accurate and successful because of gene editing technology. This might result in lower healthcare expenses and better patient outcomes. New intellectual property rights could be established because of the advancement of gene editing technologies, which would lead to a sharp rise in the number of patent applications.
Market Segmentation:
Segmentation 1: by Offering
• Gene Editing Products
• Gene Editing Services
Based on offering, the gene editing products segment in the global gene editing technologies market dominated in FY2022.
Segmentation 2: by Technology
• CRISPR Gene Editing Technology
• Non-CRISPR Gene Editing Technology
Based on technology, the global gene editing technologies market was dominated by the CRISPR gene editing technology segment in FY2022.
Segmentation 3: by Application
• Agriculture
• Biomedical
Based on application, the biomedical segment accounted for the largest share of the global gene editing technologies market in FY2022.
Segmentation 4: by End User
• Academic Institutes and Research Centres
• Life Sciences Companies
• Contract Research Organizations (CROs)/ Contract Manufacturing Organizations (CMOs)
Based on end user, the global gene editing technologies market is dominated by the life sciences companies segment in FY2022.
Segmentation 5: by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World
In 2022 the North America gene editing technologies market dominated the global market with a 42.85% market share, and it is expected to hold its dominance throughout the forecast period 2023-2032. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 29.64% during the forecast period 2023-2032.
Recent Developments in the Global Gene Editing Technologies Market
• In March 2023, Seamless Therapeutics launched with $12.5 million seed financing to advance a transformative gene editing platform based on programmable precision designer recombinases.
• In June 2022, Precision BioSciences, Inc. entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG to develop a custom ARCUS nuclease that would be designed to insert, in vivo, a therapeutic transgene at a “safe harbor” location in the genome as a potential one-time transformative treatment option for diseases including certain hemoglobinopathies such as sickle cell disease and beta-thalassemia.
• In November 2021, Cytovia Therapeutics, Inc. and Cellectis S.A. expanded their TALEN gene-edited iNK partnership to enable broader collaboration in China.
• In February 2022, Integrated DNA Technologies, Inc. (IDT), a provider of global genomics solutions, introduced Alt-R HDR Donor Blocks to support researchers in advancing scientific breakthroughs in gene editing. This enhanced solution was designed to improve homology-directed repair (HDR) rates in large fragment knock-in experiments.
• In March 2023, Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) Application for NTLA-2002. This was an in vivo investigational therapy based on CRISPR, intended for the treatment of Hereditary Angioedema (HAE).
• In April 2022, Thermo Fisher Scientific Inc.'s latest Gibco CTS TrueCut Cas9 Protein, manufactured under Good Manufacturing Practices (GMP), facilitates genome editing for both research and manufacturing purposes, including research on CAR T-cell therapy.
• In November 2022, Ionis Pharmaceuticals, Inc. and Metagenomi announced a collaboration that may bring together Ionis' extensive knowledge in RNA-targeted therapeutics with Metagenomi's versatile next-generation gene editing systems. The aim of this collaboration was to pursue both established and new genetic targets that may offer the potential for expanding treatment options for patients.
Demand - Drivers and Limitations
The following are the demand drivers for the global gene editing technologies market:
• Introduction of New Technologies Fuelling the Growth of Gene Editing Technologies
• Increasing Investments and Funding Opportunities in Gene Editing Space
• Increased Demand for Personalized Medicines
The market is expected to face some limitations due to the following challenges:
• Limited Expertise and Facilities for Gene Editing Technologies
• Ethical Considerations and Their Consequences Regarding Human Gene Editing
Analyst View
According to Akash Mhaskar, Principal Analyst, BIS Research, “The global gene editing technologies market is flourishing with the advent of time and the introduction of new technologies in the gene editing industry. There is constant ongoing research for the development of novel gene editing technologies. The global gene editing technologies market has witnessed a steady growth in the number of new entrants and investments in gene editing technologies, thereby driving a surge in demand for gene editing products. This trend is also expected to continue over the forecast period. Therefore, the impact of the aforementioned factors is expected to drive the global gene editing technologies market in the near future.”
Gene Editing Technologies Market - A Global and Regional Analysis
Focus on Offering, Technology, Application, End User, and Region - Analysis and Forecast, 2023-2032
Some Faq's
Frequently Asked Questions
The term gene editing technologies describes a group of methods used to precisely alter the genetic code of living things. These methods give scientists the ability to specifically modify certain genes or DNA sequences, changing how those genes are expressed or function. Although there are many various kinds of gene editing tools, CRISPR-Cas9 is the one that is most frequently employed. This technique is based on a bacterial defense mechanism that directs the Cas9 protein to specific places in the genome where it can cut DNA using RNA molecules. By delivering a fresh DNA strand that can be inserted into the genome at the cut place, scientists can then employ this process to make precise alterations to the DNA sequence.
New technologies and methods are rapidly emerging to enhance the manufacture and delivery of these medicines, which is driving the market for gene editing technologies. Here are some prevalent patterns in the industry:
· Growing focus on gene therapies: Gene therapy is a rapidly growing field in the healthcare industry, and gene editing technologies are playing a major role in the development of gene therapies. Gene editing tools such as CRISPR-Cas9, zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), and meganucleases have made it possible to precisely edit the DNA of cells, opening new possibilities for treating genetic disorders that were previously untreatable.
· Leveraging collaboration is a major key strategy to create opportunities for gene editing technologies: The non-CRISPR-based gene editing market is oligopolistic in nature and consists of very few players. To maintain their market presence and position, and profits while keeping pricing pressure under consideration, the companies must adopt key strategies such as mergers and acquisitions (M&A), new offerings, and business expansions to diversify their business portfolio.
These are only a few illustrations of the major developments in the industry for gene editing technologies. Emerging innovations and technologies are anticipated to emerge as the area develops further, helping to influence the industry's future.
The global gene editing technologies market is currently witnessing several developments, primarily aimed toward bringing new products and services. Major manufacturers of gene editing products, along with the service providers, are actively undertaking significant business strategies to translate success in research and development into the commercial clinical setting. Companies such as Cellectis S.A., Merck KGaA, Thermo Fisher Scientific Inc., and CRISPR Therapeutics AG have majorly adopted partnerships, collaborations, and joint venture strategies.
A new entrant can focus on various gene editing product offerings by established players. The market is fragmented with established market leaders such as Cellectis S.A., Merck KGaA, Thermo Fisher Scientific Inc., and CRISPR Therapeutics AG, who have had their presence in the market for the past many years. The new entrants can focus on their strategy of product launches and global expansions for gene editing technologies.
· The major USP of the report is the inclusion of a wide range of gene editing products, including kits and enzymes, libraries, antibodies, accessories, and gene editing services that utilize CRISPR, ZFNs, TALENs, and meganucleases for various applications such as agricultural, biomedical, and others.
· The report provides numerical projections for the application in each region and country.
· Apart from this, the report focuses on key trends observed in the global gene editing technologies market.
· The report also comprises key regulations, competitive landscape, key drivers and restraints, patent analysis, business model analysis, and company profiles with a detailed analysis of the strategies undertaken by the major company to strengthen its market presence.
· Companies that manufacture and commercialize gene editing products as well as provide gene editing services
· Any new entrant that wants to know where the opportunities lie in the gene editing technologies market
· Any established player that wants to expand its product portfolio or business in a new geography
Similar Product
You may also like